Biological availability of inhaled fluticasone propionate in horses.
Healthy horses received aerosolised, intranasal or oral doses of 3 mg of fluticasone propionate evenly divided over morning and evening treatments for seven days. The bioavailability of the drug was determined in terms of the suppression of the endogenous cortisol concentrations in the horses during the period of treatment. The horses which received the aerosolised drug had significantly lower concentrations of endogenous cortisol on days 5 and 8 than the horses which received aerosolised placebo. The horses which received nasal and oral doses of fluticasone propionate showed no significant changes in their endogenous cortisol concentrations.
Laan
T T J M
TT
Faculty of Veterinary Medicine, Department of Equine Sciences, Internal Medicine Section, Utrecht University, PO Box 80152, 3508 TD, Utrecht, The Netherlands.
Westermann
C M
CM
Dijkstra
A V
AV
van Nieuwstadt
R A
RA
Fink-Gremmels
J
J
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000284:Administration, Oral; D000402:Airway Obstruction / Q000188:drug therapy / Q000662:veterinary*; D000730:Androstadienes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D018592:Cross-Over Studies; D005260:Female; D000068298:Fluticasone; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D006854:Hydrocortisone / Q000097:blood; D011897:Random Allocation; D016896:Treatment Outcome
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone; D006854:Hydrocortisone